cabergoline has been researched along with Pleural Effusion in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genís-Batlle, D; Haro-Estarriol, M; Obrador-Lagares, A; Rodríguez-Jerez, F; Sabater-Talaverano, G; Sendra-Salillas, S | 1 |
| Gayete, A; Grau, S; Orozco-Levi, M; Ramírez-Sarmiento, A; Villavicencio, C | 1 |
| Demedts, M; Dom, R; Frans, E | 1 |
3 other study(ies) available for cabergoline and Pleural Effusion
| Article | Year |
|---|---|
[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Humans; Hypertension, Pulmonary; Male; Parkinson Disease; Pleural Effusion | 2009 |
[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Humans; Lung Diseases; Male; Pleural Effusion; Time Factors | 2007 |
Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
Topics: Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Humans; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion | 1992 |